Table 1.
HRs and 95% CIs for the primary and secondary end points in the RECORD study, according to intention-to-treat and per-protocol analyses (12,22)
| End point | Intention-to-treat analysis | Dual therapy per-protocol analysis | ||||
|---|---|---|---|---|---|---|
| HR (95% CI) | Rosiglitazone (n) | Metformin/sulfonylurea (n) | HR (95% CI) | Rosiglitazone (n) | Metformin/sulfonylurea (n) | |
| Primary (CV death or CV hospitalization) | 0.99 (0.85–1.16) | 321 | 323 | 1.03 (0.86–1.23) | 237 | 255 |
| MACE | 0.93 (0.74–1.15) | 154 | 165 | 0.89 (0.68–1.17) | 94 | 117 |
| Myocardial infarction | 1.14 (0.80–1.63) | 64 | 56 | 1.18 (0.78–1.78) | 47 | 44 |
| Stroke | 0.72 (0.49–1.06) | 46 | 63 | 0.69 (0.45–1.08) | 32 | 51 |
| CV death | 0.84 (0.59–1.18) | 60 | 71 | 0.75 (0.44–1.27) | 23 | 34 |
| Heart failure | 2.10 (1.35–3.27) | 61 | 29 | 1.95 (1.16–3.29) | 39 | 22 |
| Total mortality | 0.86 (0.68–1.08) | 111 | 139 | 0.69 (0.44–1.11) | 29 | 46 |
MACE, composite of CV death + MI + stroke.